Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...

Clinical Trials

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

Phase 2

Recruiting

Conditions: Heart Failure

Interventions: Drug: REGN5381
Drug: Matching Placebo

First Posted Date: 2022-04-29

Last Posted Date: 2024-04-19

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT05353166

Locations: 🇭🇺
Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Pest, Hungary
🇵🇱
Gornoslaskie Centrum Medyczne Szpital W Ochojcu, Katowice, Poland
🇵🇱
Central Clinical Hospital, Lodz, Poland

and more 9 locations

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Phase 3

Recruiting

Conditions: Melanoma

Interventions: Drug: Fianlimab
Drug: Pembrolizumab
Drug: Cemiplimab
Drug: Placebo

First Posted Date: 2022-04-29

Last Posted Date: 2024-10-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 1535

Registration Number: NCT05352672

Locations: 🇺🇸
Atlantic Health System - Morristown Medical Center, Morristown, New Jersey, United States
🇦🇷
Fundacion Cenit para la Investigacion en Neurociencias, Buenos Aires, Argentina
🇦🇷
DIABAID - Instituto de Asistencia Integral en Diabetes, Buenos Aires, Argentina

and more 216 locations

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Other: Non-Interventional

First Posted Date: 2022-04-21

Last Posted Date: 2023-10-19

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 595

Registration Number: NCT05338892

Locations: 🇬🇧
Regeneron Research Facility, Nottingham, United Kingdom

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma

Completed

Conditions: Relapsed/Refractory Follicular Lymphoma

Interventions: Other: Non-Interventional

First Posted Date: 2022-04-21

Last Posted Date: 2023-10-18

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 247

Registration Number: NCT05338879

Locations: 🇬🇧
Regeneron Research Facility, Nottingham, United Kingdom

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: REGN15160 (SC)
Drug: REGN15160 (IV)
Drug: Matching Placebo (IV)
Drug: Matching Placebo (SC)

First Posted Date: 2022-03-24

Last Posted Date: 2023-02-23

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 104

Registration Number: NCT05293678

Locations: 🇧🇪
Regeneron Study Site, Leuven, Belgium

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN9035
Drug: REGN5381
Other: Placebo

First Posted Date: 2022-03-22

Last Posted Date: 2024-04-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 93

Registration Number: NCT05291546

Locations: 🇧🇪
Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven, Belgium
🇩🇪
Charite Research Organisation GmbH, Berlin, Germany

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Metastatic Solid Tumor

Interventions: Drug: 89Zr˗DFO˗REGN5054
Drug: cemiplimab

First Posted Date: 2022-02-28

Last Posted Date: 2024-12-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT05259709

Locations: 🇳🇱
UMC Groningen, Groningen, Netherlands

Compassionate Use of Pozelimab

First Posted Date: 2022-02-09

Last Posted Date: 2024-11-08

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT05232110

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Completed

Conditions: Moderate-to-severe Atopic Dermatitis

Interventions: Drug: dupilumab

First Posted Date: 2022-01-24

Last Posted Date: 2023-09-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT05203380

Locations: 🇺🇸
DermAssociates, LLC, Rockville, Maryland, United States
🇺🇸
Clinical Research Center of Alabama, LLC, Birmingham, Alabama, United States
🇺🇸
Pediatric Skin Research, LLC, Coral Gables, Florida, United States

and more 7 locations

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

Phase 1

Completed

Conditions: Chronic Stable Illness
Healthy

Interventions: Drug: Casirivimab+Imdevimab

First Posted Date: 2022-01-06

Last Posted Date: 2022-06-21

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT05181683

Locations: 🇺🇸
Regeneron StudySite, Winter Park, Florida, United States
🇺🇸
Regeneron Study Site, Miami, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy